Cervical Carcinoma
Conditions
Keywords
Cervical Carcinoma, HepaSphere
Brief summary
The purpose of this study is to evaluate the safety and efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) for cervical carcinoma.
Detailed description
By enrolling patients with cervical carcinoma adapted to enrolled criteria, this study will document for the first time the safety and the short and long term efficacy of HepaSphere interventional therapy using digital subtraction angiography(DSA) for cervical carcinoma.
Interventions
cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography(DSA)
Sponsors
Study design
Eligibility
Inclusion criteria
1. Age:18-80 2. Karnofsky performance status \>60 3. Diagnosis of cervical carcinoma based on histology or the current accepted radiological measures. 4. Classification tumor,nodes,metastasis-classification(TNM) stage: Ⅱ,Ⅲ,Ⅳ 5. Will receive interventional therapy 6. Life expectancy: Greater than 3 months 7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities 8. Ability to understand the study protocol and a willingness to sign a written informed consent document
Exclusion criteria
1. Patients with other primary tumor except cervical carcinoma 2. History of coagulation disorders or anemia
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of participants with Adverse events | 1 year |
Secondary
| Measure | Time frame |
|---|---|
| Progress free disease (PFS) | 1 year |
| Overall survival (OS) | 3 year |
| Percentage of lesions interventional therapy that show no sign of recurrence 12 months after | 1 year |
Countries
China